Probucol in the treatment of non-alcoholic steatohepatitis: A double-blind randomized controlled study

Journal of Hepatology

Volumn 38, Issue 4, 2003, Pages 414-418

  Merat, Shahin ^a   Malekzadeh, Reza ^a   Sohrabi, Masoud Reza ^a   Sotoudeh, Masoud ^a   Rakhshani, Nasser ^a   Sohrabpour, Amir Ali ^a   Naserimoghadam, Siavosh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Probucol

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; PLACEBO; PROBUCOL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLISTER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME BLOOD LEVEL; FATTY LIVER; FEMALE; FLU LIKE SYNDROME; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URTICARIA;

EID: 0037383865     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00441-5     Document Type: Article

References (29)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434.
2. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137.
3. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-723.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
5. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664.
6. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow up study of forty-two patients for up to 21 years. Hepatology 1990;11:74.
7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413.
8. Knobler H, Schattner A, Zhornicki T, Malnick S, Keter D, Sokolovskaya N, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. Q J Med 1999;92:87-96.
9. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21(1):27-41.
10. Araki T, Kitaoka H. Antioxidative properties of probucol estimated by the reactivity with superoxide and by electrochemical oxidation. Chem Pharm Bull (Tokyo) 2001;49:943-947.
11. Merat S, Malekzadeh R, Sohrabi MR, Nasseri-Moghaddam S, Mikaeli J, Farahvash M, et al. Probucol in non-alcoholic steatohepatitis: preliminary report (abstract). J Gastroenterol Hepatol 2002;17(Suppl):A523.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
13. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81-88.
14. Keeffe EB, Adesman PW, Stenzel P, Palmer RM. Steatosis and cirrhosis in an obese diabetic: resolution of fatty liver by fasting. Dig Dis Sci 1987;32:441.
15. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
16. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic steatohepatitis: a pilot study. Hepatology 1996;23:1464.
17. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (letter). J Hepatol 1999;31:384.
18. Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
19. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998.
20. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894.
21. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
22. Ahdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96(9):2711-2717.
23. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734.
24. Noguchi N, Niki E. Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis. Free Radic Biol Med 2000;28:1538-1546.
25. Thiery V, Coudert G, Bizot-Espiard JG, Pfeiffer P, Renard P, Lindenbaum A, et al. A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation. J Med Chem 2001;44:3904-3914.
26. Tardif JC, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, et al. The multivitamins and probucol study group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-372.
27. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829-2835.
28. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995;11:551-554.
29. Ito M, Suzuki Y, Ishihara M, Suzuki Y. Anti-ulcer effects of antioxidants: effect of probucol. Eur J Pharmacol 1998;354:189-196.